miR299a-5p promotes renal fibrosis by suppressing the antifibrotic actions of follistatin.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 01 2021
Historique:
received: 11 06 2020
accepted: 15 12 2020
entrez: 9 1 2021
pubmed: 10 1 2021
medline: 14 9 2021
Statut: epublish

Résumé

Caveolin-1 (cav-1), an integral protein of the membrane microdomains caveolae, is required for synthesis of matrix proteins by glomerular mesangial cells (MC). Previously, we demonstrated that the antifibrotic protein follistatin (FST) is transcriptionally upregulated in cav-1 knockout MC and that its administration is protective against renal fibrosis. Here, we screened cav-1 wild-type and knockout MC for FST-targeting microRNAs in order to identity novel antifibrotic therapeutic targets. We identified that miR299a-5p was significantly suppressed in cav-1 knockout MC, and this was associated with stabilization of the FST 3'UTR. Overexpression and inhibition studies confirmed the role of miR299a-5p in regulating FST expression. Furthermore, the profibrotic cytokine TGFβ1 was found to stimulate the expression of miR299a-5p and, in turn, downregulate FST. Through inhibition of FST, miR299a-5p overexpression augmented, while miR299a-5p inhibition diminished TGFβ1 profibrotic responses, whereas miR299a-5p overexpression re-enabled cav-1 knockout MC to respond to TGFβ1. In vivo, miR299a-5p was upregulated in the kidneys of mice with chronic kidney disease (CKD). miR299a-5p inhibition protected these mice against renal fibrosis and CKD severity. Our data demonstrate that miR299a-5p is an important post-transcriptional regulator of FST, with its upregulation an important pathogenic contributor to renal fibrosis. Thus, miR299a-5p inhibition offers a potential novel therapeutic approach for CKD.

Identifiants

pubmed: 33420269
doi: 10.1038/s41598-020-80199-z
pii: 10.1038/s41598-020-80199-z
pmc: PMC7794215
doi:

Substances chimiques

Cav1 protein, mouse 0
Caveolin 1 0
Follistatin 0
MIRN299 microRNA, mouse 0
MicroRNAs 0
Transforming Growth Factor beta1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

88

Subventions

Organisme : CIHR
ID : MOP 136868
Pays : Canada

Références

Nephrology (Carlton). 2020 Sep;25(9):659-666
pubmed: 32034833
Kidney Int. 2019 Mar;95(3):506-517
pubmed: 30598193
Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i37-i45
pubmed: 24030832
J Allergy Clin Immunol. 2006 Jan;117(1):111-8
pubmed: 16387593
J Cell Sci. 2018 Feb 20;131(4):
pubmed: 29361535
Transplant Direct. 2016 Jun 06;2(7):e87
pubmed: 27830181
Nat Rev Nephrol. 2015 Jan;11(1):23-33
pubmed: 25385286
Nat Rev Genet. 2008 Feb;9(2):102-14
pubmed: 18197166
Oncogene. 2014 Oct 30;33(44):5173-82
pubmed: 24166498
Mol Ther. 2015 Jan;23(1):192-201
pubmed: 25322757
Dev Cell. 2004 May;6(5):673-84
pubmed: 15130492
Pediatr Nephrol. 2007 Dec;22(12):2011-22
pubmed: 17647026
Sci Adv. 2020 May 08;6(19):eaaz7492
pubmed: 32426485
J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S190-7
pubmed: 1600136
J Am Soc Nephrol. 2017 Jun;28(6):1686-1696
pubmed: 28232619
Front Physiol. 2015 Feb 20;6:50
pubmed: 25750628
J Biol Chem. 2008 Jul 11;283(28):19371-8
pubmed: 18453534
Genome Biol. 2002;3(3):REVIEWS0004
pubmed: 11897027
Cytokine Growth Factor Rev. 2013 Jun;24(3):285-95
pubmed: 23541927
Am J Physiol Renal Physiol. 2008 Jul;295(1):F153-64
pubmed: 18434385
RNA Biol. 2012 May;9(5):563-76
pubmed: 22614827
Anesth Analg. 2018 Feb;126(2):670-681
pubmed: 28922229
J Am Soc Nephrol. 2005 Jun;16(6):1733-41
pubmed: 15829708
Am J Respir Cell Mol Biol. 2012 Dec;47(6):879-87
pubmed: 23043088
Nat Rev Nephrol. 2011 Oct 18;7(12):684-96
pubmed: 22009250
Sci Rep. 2016 Apr 15;6:24566
pubmed: 27080144
Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1466-76
pubmed: 23946291
Antioxid Redox Signal. 2019 Sep 10;31(8):551-571
pubmed: 31184201
Diabetologia. 2013 Sep;56(9):2068-77
pubmed: 23793581
J Vis Exp. 2013 Nov 30;(81):
pubmed: 24326287
Skelet Muscle. 2015 Oct 09;5:34
pubmed: 26457176
Cell Tissue Res. 2012 Jan;347(1):141-54
pubmed: 22105921
Nephrol Dial Transplant. 2007 Sep;22 Suppl 9:ix26-30
pubmed: 17998229
Front Physiol. 2015 Apr 28;6:121
pubmed: 25972812
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9306-11
pubmed: 11459935
J Am Soc Nephrol. 2005 Jun;16(6):1661-72
pubmed: 15814837
Curr Opin Nephrol Hypertens. 2019 May;28(3):203-210
pubmed: 30893214
BMC Nephrol. 2016 May 12;17(1):47
pubmed: 27176224
Kidney Int. 1996 Jun;49(6):1583-5
pubmed: 8743459
J Am Soc Nephrol. 2009 Jun;20(6):1179-87
pubmed: 19470685
J Pharmacol Exp Ther. 2014 May;349(2):355-71
pubmed: 24627466
Sci Rep. 2016 Mar 01;6:22442
pubmed: 26928825
J Autoimmun. 2009 May-Jun;32(3-4):246-53
pubmed: 19345069
Int J Physiol Pathophysiol Pharmacol. 2012;4(3):167-73
pubmed: 23071874
Endocrinology. 2004 Jun;145(6):2753-9
pubmed: 15001548
J Cell Physiol. 2006 Apr;207(1):40-8
pubmed: 16245315
Nucleic Acids Res. 2014;42(16):10720-30
pubmed: 25159612
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):101-6
pubmed: 22037168
Kidney Int. 2019 Nov;96(5):1134-1149
pubmed: 31492508
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
FASEB J. 1987 Oct;1(4):272-81
pubmed: 3308611
Oncol Lett. 2016 Jul;12(1):741-747
pubmed: 27347210
Transgenic Res. 2017 Feb;26(1):25-36
pubmed: 27787698
Kidney Int. 2010 Dec;78(11):1136-53
pubmed: 20736988
Cell Commun Signal. 2019 Apr 17;17(1):37
pubmed: 30995923
Biomed Res Int. 2014;2014:376191
pubmed: 24883308
Biomed Pharmacother. 2018 May;101:670-681
pubmed: 29518614
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143
pubmed: 28918016
Mol Ther. 2017 Apr 5;25(4):870-879
pubmed: 28279643
Am J Respir Crit Care Med. 2005 Sep 15;172(6):713-20
pubmed: 15976370
Gene Ther. 2011 Dec;18(12):1104-10
pubmed: 21525952
Cell Signal. 2007 Aug;19(8):1690-700
pubmed: 17446044

Auteurs

Neel Mehta (N)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Renzhong Li (R)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Dan Zhang (D)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Asfia Soomro (A)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Juehua He (J)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Ivan Zhang (I)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Melissa MacDonald (M)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Bo Gao (B)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.

Joan C Krepinsky (JC)

Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada. krepinj@mcmaster.ca.
St. Joseph's Hospital, 50 Charlton Ave East, Rm T3311, Hamilton, ON, L8N 4A6, Canada. krepinj@mcmaster.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH